Skip to main navigation

Vivek Ramaswamy

Founder & CEO

Roivant Sciences

About Us
Pipeline
Our Companies
For Investors +
Join Us

Press Releases

Year

August 27, 2026

Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

August 27, 2026

Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

August 26, 2026

JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis

August 6, 2026

Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)

August 6, 2026

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

July 23, 2026

Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

July 16, 2026

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

May 20, 2026

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

May 11, 2026

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

April 2, 2026

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 17

Print Page
Email Alerts
RSS Feeds
IR Contacts

© 2026 Roivant Sciences Ltd.

Careers Privacy Policy

Follow us on LinkedIn